North America

A new Lp(a) threshold could reshape cardiovascular risk assessment

Prostate Cancer Value Starts Counting Cognition

Servier’s $2.65B Muscular Dystrophy Deal Turns Rare Neurology Into a Commercial Priority

Alzheimer’s Blood Testing Moves the Disease Clock Earlier

Can cortisol become the next target in type 2 diabetes?

Alpha Radioligand Therapy Moves Prostate Cancer Into a New Infrastructure Test

A Urine Test for Alzheimer’s Would Change the Access Conversation

AI Multiomics Moves Into the Trial Stratification Layer

A New CELMoD Raises the Bar in Relapsed Myeloma
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
